The radiation dose-response of the human spinal cord
- PMID: 18243570
- DOI: 10.1016/j.ijrobp.2007.11.075
The radiation dose-response of the human spinal cord
Abstract
Purpose: To characterize the radiation dose-response of the human spinal cord.
Methods and materials: Because no single institution has sufficient data to establish a dose-response function for the human spinal cord, published reports were combined. Requisite data were dose and fractionation, number of patients at risk, number of myelopathy cases, and survival experience of the population. Eight data points for cervical myelopathy were obtained from five reports. Using maximum likelihood estimation correcting for the survival experience of the population, estimates were obtained for the median tolerance dose, slope parameter, and alpha/beta ratio in a logistic dose-response function. An adequate fit to thoracic data was not possible. Hyperbaric oxygen treatments involving the cervical cord were also analyzed.
Results: The estimate of the median tolerance dose (cervical cord) was 69.4 Gy (95% confidence interval, 66.4-72.6). The alpha/beta = 0.87 Gy. At 45 Gy, the (extrapolated) probability of myelopathy is 0.03%; and at 50 Gy, 0.2%. The dose for a 5% myelopathy rate is 59.3 Gy. Graphical analysis indicates that the sensitivity of the thoracic cord is less than that of the cervical cord. There appears to be a sensitizing effect from hyperbaric oxygen treatment.
Conclusions: The estimate of alpha/beta is smaller than usually quoted, but values this small were found in some studies. Using alpha/beta = 0.87 Gy, one would expect a considerable advantage by decreasing the dose/fraction to less than 2 Gy. These results were obtained from only single fractions/day and should not be applied uncritically to hyperfractionation.
Similar articles
-
Proposal of human spinal cord reirradiation dose based on collection of data from 40 patients.Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):851-5. doi: 10.1016/j.ijrobp.2004.06.016. Int J Radiat Oncol Biol Phys. 2005. PMID: 15708265 Review.
-
Variation in radiation sensitivity and repair kinetics in different parts of the spinal cord.Acta Oncol. 2008;47(5):928-36. doi: 10.1080/02841860701864668. Acta Oncol. 2008. PMID: 18568487
-
Update of human spinal cord reirradiation tolerance based on additional data from 38 patients.Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1446-9. doi: 10.1016/j.ijrobp.2006.07.1383. Epub 2006 Nov 2. Int J Radiat Oncol Biol Phys. 2006. PMID: 17084560 Review.
-
Radiation dose-volume effects in the spinal cord.Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S42-9. doi: 10.1016/j.ijrobp.2009.04.095. Int J Radiat Oncol Biol Phys. 2010. PMID: 20171517 Review.
-
Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery.Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2025-32. doi: 10.1016/j.ijrobp.2011.03.004. Epub 2011 Apr 29. Int J Radiat Oncol Biol Phys. 2012. PMID: 21531516
Cited by
-
Radiation myelopathy following stereotactic body radiation therapy for spine metastases.J Neurooncol. 2022 Aug;159(1):23-31. doi: 10.1007/s11060-022-04037-0. Epub 2022 Jun 23. J Neurooncol. 2022. PMID: 35737172 Review.
-
Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib.Radiat Oncol. 2015 Jan 29;10:29. doi: 10.1186/s13014-015-0334-7. Radiat Oncol. 2015. PMID: 25631068 Free PMC article.
-
Lumbosacral plexopathy: A rare long term complication of concomitant chemo-radiation for cervical cancer.Gynecol Oncol Res Pract. 2015 Dec 4;2:12. doi: 10.1186/s40661-015-0019-9. eCollection 2015. Gynecol Oncol Res Pract. 2015. PMID: 27231572 Free PMC article.
-
Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1442-57. doi: 10.1016/j.ijrobp.2010.07.1977. Epub 2010 Oct 8. Int J Radiat Oncol Biol Phys. 2011. PMID: 20934273 Free PMC article.
-
New Challenges of Treatment for Locally Advanced Head and Neck Cancers in the Covid-19 Pandemic Era.J Clin Med. 2021 Feb 4;10(4):587. doi: 10.3390/jcm10040587. J Clin Med. 2021. PMID: 33557273 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources